drugset / Trial / NCT00888004
Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Disease Patients
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study will evaluate the safety and efficacy of administration of AFQ056 in combination with L-dopa, in reducing the number of L-dopa related dyskinesias in Parkinson's disease patients.
Timeline
- Start
- 2009-03
- Primary completion
- 2009-08
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mavoglurant | Small molecule | 25 mg | Oral |
| Subject | Mavoglurant | Small molecule | 150 mg | Oral |